LIBERATE heart attack trial treats first patient
The first patient has been treated in the LIBERATE clinical study to evaluate glenzocimab efficacy in myocardial infarction, which involves BHP members the University of Birmingham and University H…
Aston University launches SPARK The Midlands to support health tech innovation
Aston University, a member of BHP, has launched SPARK The Midlands, a network which aims to bridge the gap between medical research discoveries of novel therapeutics, medical devices and diagn…
New treatment combination may improve outcomes for children with rare cancers
Children who develop neuroblastomas, a rare form of cancer which develops in nerve cells, may benefit from receiving certain anti-tumour drugs as well as chemotherapy, a new trial has found.
The…
Professor Amos Burke appointed Director of Birmingham’s Cancer Research UK Clinical Trials Unit (CRCTU)
Professor Amos Burke has been appointed as the new Director of the Cancer Research UK Clinical Trials Unit, based at BHP founder-member the University of Birmingham.
Professor Burke – a paediatr…
Epilepsy in pregnancy – new project to create personalised care for at-risk mums
Pregnant women with epilepsy could see a major improvement in the care they receive through a new cross-BHP project led by the University of Birmingham with Birmingham Women’s and Children’s Hospit…
Eye-safe laser technology to diagnose traumatic brain injury
Researchers from BHP founder-member the University of Birmingham have designed and developed a novel diagnostic device designed for the early detection of traumatic brain injury (TBI), wh…